Wafik S. El-Deiry, MD, PhD, FACP
@weldeiry.bsky.social
Physician-Scientist Oncologist, Director Legorreta Cancer Center, Associate Dean, past Faculty Exec Cmte member, Brown Univ, ACS Professor, Chair, WIN Consortium in Precision Oncology, Entrepreneur, Boat Captain, joined Nov 16 ‘24 Pubs: tinyurl.com/s98xg3u
Pinned
I’m here at @BrownUniversity Family Weekend on the College Green to speak with you about exciting developments at the #LegorretaCancerCenter over the last few years. As a colon cancer doctor my messa...
TikTok video by weldeiry
www.tiktok.com
On 10-26-2024 I was at Brown University Family Weekend on College Green to share exciting progress at #LegorretaCancerCenter.
As a colon cancer doctor my message was to make sure you get your screening colonoscopy to prevent colon cancer as this could save your life.
www.tiktok.com/t/ZTYLaQo9J/
As a colon cancer doctor my message was to make sure you get your screening colonoscopy to prevent colon cancer as this could save your life.
www.tiktok.com/t/ZTYLaQo9J/
RI Doctor Claims AI Medical Firm Fired Him After Raising Concerns About FDA and HIPAA Compliance
www.golocalprov.com/business/ri-...
www.golocalprov.com/business/ri-...
GoLocalProv | Business | RI Doctor Claims AI Medical Firm Fired Him After Raising Concerns About FDA and HIPAA Compliance
As artificial intelligence continues to explode into a multi-trillion-dollar sector dominated by the biggest corporations in America, the industry is also showing signs of fraying - and one business b...
www.golocalprov.com
November 28, 2025 at 2:38 PM
RI Doctor Claims AI Medical Firm Fired Him After Raising Concerns About FDA and HIPAA Compliance
www.golocalprov.com/business/ri-...
www.golocalprov.com/business/ri-...
Special Interview with Dr. Wafik S. El-Deiry — New insights into the potential role of new technologies in overcoming cancer drug resistance in the future
www.oaepublish.com/interviews/c...
www.oaepublish.com/interviews/c...
Cancer Drug Resistance - OAE Publishing Inc.
Cancer Drug Resistance is a peer-reviewed journal led by Editor-in-Chief Godefridus J. (Frits) Peters, covering drug resistance research on breast cancer, lymphatic cancer, hematological malignancies,...
www.oaepublish.com
November 28, 2025 at 1:43 PM
Special Interview with Dr. Wafik S. El-Deiry — New insights into the potential role of new technologies in overcoming cancer drug resistance in the future
www.oaepublish.com/interviews/c...
www.oaepublish.com/interviews/c...
What if RFK Jr. reacted to his cousin's terminal cancer as JFK reacted to his baby's death?
www.statnews.com/2025/11/26/t...
www.statnews.com/2025/11/26/t...
What if RFK Jr. reacted to his cousin’s terminal cancer as JFK reacted to his baby’s death?
When President Kennedy’s newborn son died in 1963, it galvanized research. A new Kennedy family tragedy should spur RFK Jr. to support cancer research, not cut it.
www.statnews.com
November 28, 2025 at 3:44 AM
What if RFK Jr. reacted to his cousin's terminal cancer as JFK reacted to his baby's death?
www.statnews.com/2025/11/26/t...
www.statnews.com/2025/11/26/t...
Intratumoral cancer therapy market set to grow sharply through 2033
www.thepharmaletter.com/pharmaceutic...
www.thepharmaletter.com/pharmaceutic...
Intratumoral cancer therapy market set to grow sharply through 2033
The global market for intratumoral cancer therapies is set for a long growth runway, according to new sector analysis from DataM Intelligence, outlining rising clinical use of oncolytic viruses, adeno...
www.thepharmaletter.com
November 28, 2025 at 3:35 AM
Intratumoral cancer therapy market set to grow sharply through 2033
www.thepharmaletter.com/pharmaceutic...
www.thepharmaletter.com/pharmaceutic...
New drug combo nearly doubles survival for BRAF-mutated lung cancer patients, trial shows
First-line use of encorafenib and binimetinib in BRAF V600E NSCLC recorded a median overall survival of 47.6 months, according to data presented at the ESMO congress.
www.jpost.com/health-and-w...
First-line use of encorafenib and binimetinib in BRAF V600E NSCLC recorded a median overall survival of 47.6 months, according to data presented at the ESMO congress.
www.jpost.com/health-and-w...
PHAROS regimen shows major gain for lung cancer patients | The Jerusalem Post
First-line use of encorafenib and binimetinib in BRAF V600E NSCLC recorded a median overall survival of 47.6 months, according to data presented at the ESMO congress.
www.jpost.com
November 28, 2025 at 3:33 AM
New drug combo nearly doubles survival for BRAF-mutated lung cancer patients, trial shows
First-line use of encorafenib and binimetinib in BRAF V600E NSCLC recorded a median overall survival of 47.6 months, according to data presented at the ESMO congress.
www.jpost.com/health-and-w...
First-line use of encorafenib and binimetinib in BRAF V600E NSCLC recorded a median overall survival of 47.6 months, according to data presented at the ESMO congress.
www.jpost.com/health-and-w...
This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results
www.fool.com/coverage/fil...
www.fool.com/coverage/fil...
This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results | The Motley Fool
One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention.
www.fool.com
November 28, 2025 at 3:28 AM
This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results
www.fool.com/coverage/fil...
www.fool.com/coverage/fil...
FOLFIRINOX shows promise as a second-line option for advanced biliary tract cancer
www.news-medical.net/news/2025112...
www.news-medical.net/news/2025112...
FOLFIRINOX shows promise as a second-line option for advanced biliary tract cancer
Biliary tract cancers, including intrahepatic, perihilar, and extrahepatic cholangiocarcinoma and gallbladder cancer, are among the most aggressive gastrointestinal malignancies.
www.news-medical.net
November 28, 2025 at 3:20 AM
FOLFIRINOX shows promise as a second-line option for advanced biliary tract cancer
www.news-medical.net/news/2025112...
www.news-medical.net/news/2025112...
This Common Drug Seems to Fight One of The Deadliest Brain Cancers
www.sciencealert.com/this-common-...
www.sciencealert.com/this-common-...
This Common Drug Seems to Fight One of The Deadliest Brain Cancers
Hydralazine has been used to treat high blood pressure for many decades, even though it's never been exactly clear how it works.
www.sciencealert.com
November 28, 2025 at 3:15 AM
This Common Drug Seems to Fight One of The Deadliest Brain Cancers
www.sciencealert.com/this-common-...
www.sciencealert.com/this-common-...
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges - Signal Transduction and Targeted Therapy
Signal Transduction and Targeted Therapy - Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
www.nature.com
November 28, 2025 at 3:12 AM
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
www.nature.com/articles/s41...
www.nature.com/articles/s41...
View of lighthouse in Barrington, RI on sunny Thanksgiving Day.
November 27, 2025 at 8:17 PM
View of lighthouse in Barrington, RI on sunny Thanksgiving Day.
Happy Thanksgiving from the #LegorretaCancerCenter @BrownUCancer @BrownMedicine @BrownUniversity @BrownUnivHealth @carenewengland
November 27, 2025 at 2:30 PM
Happy Thanksgiving from the #LegorretaCancerCenter @BrownUCancer @BrownMedicine @BrownUniversity @BrownUnivHealth @carenewengland
In my opinion, changes in funding scientific research should be evidence based in order to minimize harm👇@NIH @HHSGov @statnews @DrJBhattacharya @RobertKennedyJr
Federal biotech commission calls for retooling of scientific research infrastructure
www.statnews.com/2025/11/25/b...
Federal biotech commission calls for retooling of scientific research infrastructure
www.statnews.com/2025/11/25/b...
Federal biotech commission calls for retooling of scientific research infrastructure
A federal commission is calling for significant changes to the way the U.S. government funds and assesses scientific research.
www.statnews.com
November 27, 2025 at 1:10 AM
In my opinion, changes in funding scientific research should be evidence based in order to minimize harm👇@NIH @HHSGov @statnews @DrJBhattacharya @RobertKennedyJr
Federal biotech commission calls for retooling of scientific research infrastructure
www.statnews.com/2025/11/25/b...
Federal biotech commission calls for retooling of scientific research infrastructure
www.statnews.com/2025/11/25/b...
NSD2 targeting reverses plasticity and drug resistance in prostate cancer
www.nature.com/articles/s41...
www.nature.com/articles/s41...
NSD2 targeting reverses plasticity and drug resistance in prostate cancer - Nature
Inhibition of the histone methyltransferase NSD2 and the androgen receptor in preclinical models can reverse lineage plasticity to suppress tumour growth and promote cell death in multiple subtypes of...
www.nature.com
November 27, 2025 at 12:12 AM
NSD2 targeting reverses plasticity and drug resistance in prostate cancer
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Pleased to share Ad regarding a great opportunity @BrownMedicine and @Brownsurgical for Chief of the Division of Surgical Oncology. I encourage my qualified interested colleagues to apply and look into this as great things are happening @BrownUniversity and #LegorretaCancerCenter
November 26, 2025 at 11:59 PM
Pleased to share Ad regarding a great opportunity @BrownMedicine and @Brownsurgical for Chief of the Division of Surgical Oncology. I encourage my qualified interested colleagues to apply and look into this as great things are happening @BrownUniversity and #LegorretaCancerCenter
MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance
www.nature.com/articles/s41...
www.nature.com/articles/s41...
MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance - Nature
Nature - MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance
www.nature.com
November 26, 2025 at 11:00 AM
MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Dana-Farber Cancer Institute awarded $20 million for breast cancer research from Facebook cofounder’s foundation
It’s the largest non-federal grant for metastatic breast cancer research at Dana-Farber, officials said.
www.bostonglobe.com/2025/11/25/m...
It’s the largest non-federal grant for metastatic breast cancer research at Dana-Farber, officials said.
www.bostonglobe.com/2025/11/25/m...
Dana-Farber Cancer Institute awarded $20 million for breast cancer research from Facebook cofounder’s foundation - The Boston Globe
It’s the largest non-federal grant for metastatic breast cancer research at Dana-Farber, officials said.
www.bostonglobe.com
November 26, 2025 at 1:44 AM
Dana-Farber Cancer Institute awarded $20 million for breast cancer research from Facebook cofounder’s foundation
It’s the largest non-federal grant for metastatic breast cancer research at Dana-Farber, officials said.
www.bostonglobe.com/2025/11/25/m...
It’s the largest non-federal grant for metastatic breast cancer research at Dana-Farber, officials said.
www.bostonglobe.com/2025/11/25/m...
Penn Medicine liable for $12.25 million in cancer misdiagnosis suit, Philadelphia jury says
www.thedp.com/article/2025...
www.thedp.com/article/2025...
Penn Medicine liable for $12.25 million in cancer misdiagnosis suit, Philadelphia jury says
Penn, and the plaintiff's primary physician, Janos Tanyi, were found liable for 35%, or $12.25 million, of the total verdict.
www.thedp.com
November 26, 2025 at 1:42 AM
Penn Medicine liable for $12.25 million in cancer misdiagnosis suit, Philadelphia jury says
www.thedp.com/article/2025...
www.thedp.com/article/2025...